Good
Mostly Aligned
Patient Risk:
Low
Summary
The AI claim is largely supported by the label excerpt: in patients with type 2 diabetes without clinically evident coronary heart disease, LIPITOR is indicated to reduce risk of myocardial infarction and stroke. The claim is slightly broader/more general by referencing 'cardiovascular morbidity and mortality' and omits that the label excerpt specifies 'type 2 diabetes' and 'multiple risk factors' rather than 'diabetes' more generally.
Category Scores
Accurate Statements
LIPITOR is indicated in patients with type 2 diabetes without clinically evident coronary heart disease to reduce the risk of myocardial infarction and stroke.
14 CLINICAL STUDIES, 1.1 Prevention of Cardiovascular Disease: 'In patients with type 2 diabetes, and without clinically evident coronary heart disease... LIPITOR is indicated to: Reduce the risk of myocardial infarction; Reduce the risk of stroke.'
Unsupported Statements
LIPITOR is indicated to reduce cardiovascular morbidity and mortality in patients with diabetes without clinically evident coronary heart disease...
The provided label excerpt specifies reduction in risk of myocardial infarction and stroke, and it describes the population as 'type 2 diabetes' with 'multiple risk factors.' The claim uses broader language ('cardiovascular morbidity and mortality') and uses 'diabetes' without the label's 'type 2' and 'multiple risk factors' qualifiers.
Contradictions
Important Omissions
The AI claim does not mention that the label excerpt restricts this indication to patients with 'type 2 diabetes' and with 'multiple risk factors for coronary heart disease' (e.g., retinopathy, albuminuria, smoking, or hypertension).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The claim concerns an on-label indication for a specific population, but it is broadened beyond the label excerpt (general 'diabetes' and generalized 'morbidity and mortality'). This could affect appropriate patient selection, but it does not introduce dosing or safety instructions.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Population wording is broader/general than the label excerpt and adds 'cardiovascular morbidity and mortality' phrasing not explicitly used in the provided label text.
Suggested Improvement
Rephrase to match the excerpt: specify 'type 2 diabetes' without clinically evident coronary heart disease and include that patients have 'multiple risk factors for coronary heart disease,' and describe endpoints as 'reduce risk of myocardial infarction' and 'reduce risk of stroke.'